

«OSTEOSARCOMA ODYSSEY» Agenda & Scientific Programme

Sunday, August 30th

- 11.00-12.00 Registration (Conference Desk, Richard With)
- 12.00 Departure from Trondheim
- 12.30 Lunch
- 14.00-14.15 Welcome & General Information, Ø. S. Bruland
- 14.15-14.40 Keynote Address:
Ø. S. Bruland, Oslo: **The many faces of osteosarcoma. Some dilemmas and challenges in its current management**

#

Session 1: «The Evolution of Adjuvant Chemotherapy - I»

- Chairman:** Ø. P. Solheim
- 14.45-15.15
N. Jaffe, Houston: **High dose methotrexate with leucovorin rescue in osteosarcoma: The beginning of the Odyssey**
- 15.15-15.45
G. Sæter, Oslo: **High-grade osteosarcoma: The scope beyond the «classical patient»**
- 15.45-16.15
P. Picci, Bologna: **The role of salvage therapy - prognostication based on primary tumour's degree of necrosis following chemotherapy**
- 16.15-16.30
G. Délépine, Paris: **High value of the methotrexate seric level in osteosarcoma therapy**
- 16.30-17.00 Coffee / Tea & Refreshments

00-25.01

Session 2: «The Evolution of Adjuvant Chemotherapy - II»

- Chairman:** G. Bacci
- 17.00-17.30
R. Maas, Hamburg: **Evaluation of response to pre-operative chemotherapy by serial dynamic MR-imaging**
- 17.30-18.00
C. Arndt, Rochester: **The pediatric osteosarcoma patients treated at the Mayo Clinic**
- 18.00-18.30
S. Bielack, Münster: **Osteosarcoma: Evolution of the strategy pursued by the cooperative German - Austrian - Swiss osteosarcoma study group (COSS)**
- 18.30-18.45 **General Discussion**
- 18.45-19.30 **Poster Presentation**
- 20.15 **Dinner**

Monday, August 31th

- 07.30 **Breakfast**

Session 3: «The Evolution of Adjuvant Chemotherapy - III»

- Chairman:** N. Jaffe
- 08.45-09.05
S. Epelman, Sao Paulo: **Treatment of osteosarcoma without high dose methotrexate**
- 09.05-09.25
N. Délépine, Paris: **Our experience of «classical» osteosarcoma treated with comprehensive treatment**
- 09.25-09.45
S. Patel, Houston: **Current therapeutic strategies for adult patients with conventional and poor prognosis osteosarcoma**
- 09.45-10.15
S. Bentzen, London: **Prognosis and therapeutic progress in osteosarcoma: a statistician's view**
- 10.15-10.40 **Coffee / Tea & Refreshments**

Session 4: «Metastatic Osteosarcoma»

Chairman: P. Picci

10.40-11.10

G. Bacci, Bologna:

The treatment of osteosarcoma of the extremities with detectable lung metastases at presentation: the Rizzoli's experience

11.10-11.30

U. Pastorino, Milano:

Experience with surgical metastasectomy in osteosarcoma

11.30-11.45

J. Høie, Oslo:

Selection of patients for thoractomy - who can be cured by surgery?

11.45-12.05

Ø. S. Bruland, Oslo:

Detection of micrometastases in peripheral blood and bone marrow aspirates. A possible prognostic factor

12.05-12.15

General Discussion

12.15

Lunch

Session 5: «Experimental Radioimmunotherapy»

Chairman: A. Pihl

14.00-14.20

M. Zalutsky, Durham:

Radioimmunotherapy of osteosarcoma - will it ever work?

14.20-14.40

E. Aurlen, Oslo:

Eradication of «micrometastases» using ²¹¹At-labelled monoclonal antibodies. An in vitro model study

14.40-14.55

T. Olafsen, Oslo:

Construction and eukaryotic expression of chimeric anti-osteosarcoma TP-mabs and fragments

14.55-15.00

General Discussion

15.00-15.30

Coffee / Tea & Refreshments

Session 6: «Novel Approaches - Radiotherapy»

Chairman: Ø. S. Bruland

15.30-15.50

D. R. Olsen, Oslo:

Is osteosarcoma a radioresistant tumor? A radiobiological enigma

15.50-16.10

G. Matchak, Moscow:

Long-term results of non-surgical local treatment for osteosarcoma of the extremities

16.10-16.30

L. Moe, Oslo:

Spontaneous osteosarcoma in dogs: Clinical experience with targeted radionuclide therapy

16.30-16.40

P. Anderson, Rochester:

^{153}Sm -EDTMP therapy with stem cell support in osteosarcoma patients

16.40-16.50

G. Wiseman, Rochester:

Tumor radiation doses obtainable using ^{153}Sm -EDTMP. Dosimetric considerations

16.50-17.00

General Discussion

Session 7: «Novel Approaches - Chemotherapy»

Chairman: G. Sæter

17.00-17.30

N. Baldini, Bologna:

The role of drug resistance in osteosarcoma

17.30-17.50

A. Brach del Prever, Torino:

Experience with bone marrow ablative chemotherapy in osteosarcoma

17.50-18.00

T. Skårby, Lund:

Pharmacokinetics of cytostatics used for treatment of initially localized osteosarcoma

18.00-18.10

General Discussion

20.00

«Conference Dinner»

Tuesday, September 1st

07.30 Breakfast

Session 8: «Cell Biology of Osteosarcoma - Some New Aspects»

Chairman: N. Baldini

08.45-09.00

K. Gautvik, Oslo:

Human osteosarcoma cells in bone research

09.00-09.30

J. Novak, Lewisburg:

Interactions between plasmin, osteocalcin and oxytocin in regulation of osteosarcoma cell growth

09.30-09.45

J. O. Gordeladze, Oslo:

Alterations in osteoblastic gene expression (phenotypic change) as a function of hormonal exposure

09.45-10.00

P. Ward, St. Paul:

Characterisation of the p80 osteosarcoma-associated antigen

10.00-10.05

General Discussion

10.05-10.30

Coffee / Tea & Refreshments

Session 9: «Novel Approaches - Immunotherapy»

Chairman: P. Anderson

10.30-10.50

K. Skubitz, Minneapolis:

Inhalational IL-2 liposomes for pulmonary metastases

10.50-11.10

E. Kleinerman, Houston:

Liposome therapy: From the Bench to the Bedside

11.10-11.25

V.N. Mitin, Moscow

Prevention of lung metastasis by allogenic bone marrow transfusion in spontaneous canine osteosarcoma

11.25-11.45

F. Uckun, St. Paul:

Antitumor activity of TP3 (anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma

#

11.45-12.10

* P. Abrams, Seattle:

Hurdles faced by biotechnology companies in developing therapies for osteogenic sarcoma

12.10-12.45	General Discussion & Closing Remarks
13.00	Lunch
14.45	Arrival Tromsø

SPECIAL FEATURES

Sunday:

- 21.15 Arrival Rørvik (Dep. 22.00)

Monday:

- 12.30 Arrival Bodø (Dep. 15.00)
 - 13.00-14.00 Sight-seeing
- 19.30 Arrival Stamsund
- 21.00 Arrival Svolvær (Dep. 22.00)
- 22.00 «Raftsundet & Trollfjorden»

Tuesday:

- 01.00 Arrival Stokmarknes
- 06.45 Arrival Harstad (Dep. 08.15)
- 12.00 Arrival Finnsnes
- 13.45 «Rystraumen»
- 14.45 Arrival Tromsø

The route involves numerous scenic events. The organiser has attempted to fit the scientific programme so that these can be enjoyed.